FGFR1 and neoplasm: Considering that IP injection of the FGFR1 inhibitor PD173074 at 1 mg/kg/day has been utilized to inhibit FGFs-induced angiogenesis [57] and at 20–50 mg/kg/day to elucidate the anti-tumor effect of FGFs [58], 2 mg/kg/day was administered in our study.